Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 8:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 942 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Orthomyxoviridae Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease

NCT02883426
View directory record Official record
Conditions
Influenza
Interventions
H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV), H3N2v inactivated subvirion influenza vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 26 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Open-Label Study of H5 Vaccine in Participants of Protocol 04-077

NCT00402649
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 10 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
3
States / cities
Torrance, California • Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza

NCT02603952
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, MEDI8852, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Canoga Park, California • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population

NCT00377585
View directory record Official record
Conditions
Influenza
Interventions
Fluarix, adjuvanted influenza vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
3,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
10
States / cities
Clearwater, Florida • Coral Gables, Florida • Milford, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects

NCT04160975
View directory record Official record
Conditions
Flu, Human, Influenza, Human, Covid19
Interventions
Video about safety and effectiveness of adult seasonal flu vaccination
Behavioral
Lead sponsor
Harvard University
Other
Eligibility
18 Years to 51 Years · Male only
Enrollment
3,245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics

NCT00336453
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccination
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
6 Months to 59 Months
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Bardstown, Kentucky • St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

NCT00388583
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
17
States / cities
Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

NCT01827462
View directory record Official record
Conditions
Influenza
Interventions
Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

NCT05868382
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1010, mRNA-1010.4, mRNA-1010.6
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
10
States / cities
Hollywood, Florida • Miami, Florida • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 12, 2026, 8:41 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

NCT04579588
View directory record Official record
Conditions
Corona Virus Infection, Flu Vaccine, Immunity
Interventions
Flu shot
Biological
Lead sponsor
Stanford University
Other
Eligibility
9 Years to 64 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Study to Assess the Safety of a New Influenza Vaccine

NCT01104493
View directory record Official record
Conditions
Healthy
Interventions
Monovalent Frozen FluMist®, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 18, 2011 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

NCT04176133
View directory record Official record
Conditions
Healthy
Interventions
Entolimod, Placebo, Influenza vaccine
Drug
Lead sponsor
Robert J. Pignolo
Other
Eligibility
65 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 12, 2026, 8:41 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Elderberry for Immune Support

NCT05435144
View directory record Official record
Conditions
Upper Respiratory Tract Infection, COVID-19, Flu, Flu Like Illness, Cold
Interventions
Elderberry, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
20 Years to 65 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01579916
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Influenza Virus Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

NCT00957996
View directory record Official record
Conditions
Seasonal Influenza, Cough, Sore Throat, Nasal Congestion, Myalgia, Headache, Fatigue
Interventions
Peramivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
79
States / cities
Dothan, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 3 Interventional Results available

Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza

NCT02635724
View directory record Official record
Conditions
Influenza
Interventions
Peramivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Brooksville, Florida • Lakeland, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Flublok or Fluzone With Advax-CpG55.2 or AF03

NCT03945825
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

NCT06508320
View directory record Official record
Conditions
Influenza, SARS-CoV-2
Interventions
mRNA-1083
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 64 Years
Enrollment
931 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
12
States / cities
Hialeah, Florida • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 12, 2026, 8:41 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)

NCT07300085
View directory record Official record
Conditions
Healthy Participants
Interventions
Fluzone® High-Dose (HD) influenza vaccine, MK-1406 Injection, Placebo
Biological · Combination Product
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 49 Years
Enrollment
710 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 12, 2026, 8:41 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Response to Influenza Vaccine During Pregnancy

NCT03888989
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent inactivated influenza vaccine (IIV)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers

NCT01269723
View directory record Official record
Conditions
Smoking
Interventions
Broccoli sprout homogenate, Alfalfa sprout homogenate
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 40 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

NCT05874713
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

NCT01498718
View directory record Official record
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 12, 2026, 8:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

NCT05875961
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59, High dose A/H2N3c non-adjuvanted, Lowest dose A/H2N3c + high dose MF59, Low dose A/H2N3c + high dose MF59
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 12, 2026, 8:41 AM EDT